ReviewCancer management and research2026
The TCN1 Paradox: Unraveling the Dual Role of Transcobalamin I in Colorectal Cancer-From Metabolic Regulation to Oncogenic Signaling.
Review in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) remains a leading cause of cancer mortality. While genetic drivers are well-characterized, epigenetic alterations-particularly DNA methylation-are increasingly recognized as critical contributors. The vitamin B12 transporter Transcobalamin I (TCN1) has recently emerged as an epigenetically regulated gene with context-dependent oncogenic functions. Main Body: This review synthesized current evidence positioning TCN1 at the intersection of metabolic regulation and oncogenic signaling. We critically evaluated TCN1's consistent overexpression in CRC, its regulation by promoter methylation, and its functional interactions with the Wnt/β-catenin and Notch pathways via Integrin Beta 4 (ITGB4). Notably, we identified and explored the "TCN1 paradox"-the tissue-specific prognostic disparities observed across gastrointestinal cancers-and proposed mechanistic hypotheses to explain this divergence. We also assessed TCN1's clinical potential as a liquid biopsy biomarker, discussing analytical challenges and benchmarking requirements against established tests like SEPT9 methylation. Conclusion: TCN1 represents a promising multi-functional biomarker in CRC, linking one-carbon metabolism to tumor progression. However, significant knowledge gaps remain regarding its precise molecular mechanisms. We outline a translational roadmap prioritizing in vivo validation, prospective clinical cohorts, and therapeutic vulnerability screening to determine whether TCN1 can transition from a biological player to a clinical tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.